| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ALLC |
| Uniprot No | Q8N6M5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-409aa |
| 氨基酸序列 | MADAPKEGRLTRFLDFTQLMDMASESVGGKILFATDDFFAPAENLIKSDSPCFKEHEYTEFGKWMDGWETRRKRIPGHDWCVLRLGIQGVIRGFDVDVSYFTGDYAPRVSIQAANLEEDKLPEIPERGIRTGAAATPEEFEAIAELKSDDWSYLVPMTELKPGNPASGHNYFLVNSQQRWTHIRLNIFPDGGIARLRVFGTGQKDWTATDPKEPADLVAIAFGGVCVGFSNAKFGHPNNIIGVGGAKSMADGWETARRLDRPPILENDENGILLVPGCEWAVFRLAHPGVITRIEIDTKYFEGNAPDSCKVDGCILTTQEEAVIRQKWILPAHKWKPLLPVTKLSPNQSHLFDSLTLELQDVITHARLTIVPDGGVSRLRLRGFPSSICLLRPREKPMLKFSVSFKANP |
| 分子量 | 72 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人尿激酶(recombinant urokinase，通常缩写为r-UK或u-PA)的示例参考文献，文献信息为模拟概括，仅供参考：
---
1. **文献名称**：*"Recombinant Urokinase for Thrombolysis in Acute Myocardial Infarction: A Randomized Controlled Trial"*
**作者**：Wang et al.
**摘要**：该研究评估了重组尿激酶在急性心肌梗死患者中的溶栓疗效和安全性。结果显示，90分钟内血管再通率显著高于链激酶组，且出血风险可控，支持其作为临床溶栓药物的潜力。
2. **文献名称**：*"High-Level Expression of Recombinant Urokinase in Pichia pastoris"*
**作者**：Li & Chen
**摘要**：通过毕赤酵母表达系统高效生产重组尿激酶，优化发酵条件后酶活性提升至1200 IU/mg。研究为工业化大规模生产提供了可行方案。
3. **文献名称**：*"Comparative Pharmacokinetics of Recombinant Urokinase and Streptokinase in Rabbit Models"*
**作者**：Patel et al.
**摘要**：比较两种溶栓药物的药代动力学特性，发现重组尿激酶半衰期较短(约20分钟)，但纤维蛋白特异性更高，减少全身纤溶亢进风险。
4. **文献名称**：*"Mechanistic Insights into Plasminogen Activation by Recombinant Urokinase"*
**作者**：Kimura et al.
**摘要**：通过分子动力学模拟和体外实验，阐明重组尿激酶通过裂解纤溶酶原的Arg561-Val562键激活纤溶酶，促进血栓溶解的作用机制。
---
**注意事项**：
- 以上文献为示例，实际引用需通过学术数据库(如PubMed、Google Scholar)检索真实发表的研究。
- 重组人尿激酶的标准缩写为**u-PA**(尿激酶型纤溶酶原激活剂)或**r-UK**，建议核实术语准确性。
- 部分研究可能侧重不同应用(如癌症治疗、伤口愈合)，需根据需求筛选文献。
Recombinant urate oxidase (ALLC), also known as rasburicase, is a biotechnologically engineered version of the natural enzyme urate oxidase. Native urate oxidase, which catalyzes the conversion of uric acid into water-soluble allantoin, is absent in humans due to evolutionary gene mutations. This deficiency makes humans prone to hyperuricemia, a condition linked to gout, tumor lysis syndrome (TLS), and renal complications.
First developed in the 1990s, recombinant ALLC is produced using genetically modified organisms, typically Saccharomyces cerevisiae or Escherichia coli. Unlike the porcine-derived uricase previously used, recombinant ALLC offers higher purity, reduced immunogenicity, and scalable production. It has become a critical therapeutic agent for managing acute hyperuricemia in chemotherapy-induced TLS, rapidly lowering plasma uric acid levels to prevent kidney damage.
Clinical applications expanded after FDA approval in 2002. with PEGylated forms (e.g., pegloticase) later developed to prolong circulation time. However, immunogenicity remains a challenge, as anti-drug antibodies can cause hypersensitivity reactions or nullify efficacy. Genetic variations, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, also limit its use due to oxidative stress risks.
Ongoing research focuses on engineered variants with improved stability and reduced antigenicity, employing techniques like PEGylation, fusion proteins, or glycoengineering. These advancements aim to broaden therapeutic windows while addressing safety concerns in chronic gout management.
×
